The STRICT pilot study - Simvastatin Therapy for Reducing Inflammation in Colorectal cancer Trial

Interventions: Participants will receive standard first line chemotherapy, as chosen by their treating medical oncologist. In addition, participants will be asked to take a daily 40mg dose of simvastatin orally in the evening from the first day of chemotherapy until tumour progression or patient is withdrawn from treatment due to clinician or patient decision.
Adherence to medication will be conducted using patient diaries, completion of a monthly Medication Adherence Record Scale-5 questionnaire, and pharmacy records.
Primary outcome(s): Toxicity: Incidence of serious Grade 3 or 4 toxicity graded according to NCI CTCAE version 4.03[until tumour progression (anticipated to be <12 months)]
Study Design: Purpose: Treatment; Allocation: Non-randomised trial; Masking: Open (masking not used);Assignment: Single group;Type of endpoint: Safety/efficacy